Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 2/20 | 1.00 |
| ▸ | RARB | P10826 | 15/20 | 0.77 |
| ▸ | RARG | P13631 | 15/20 | 0.77 |
| ▸ | RARA | P10276 | 14/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 5/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRG | P48443 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tazarotenic Acid SCHEMBL29466098 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotenic Acid SCHEMBL678713 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL9337024 | 0.92 | CYP3A4 (0.84) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL14330777 | 0.92 | CYP3A4 (0.84) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL5482303 | 0.91 | CYP3A4 (0.83) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL23139544 | 0.89 | CYP3A4 (0.80) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL19560666 | 0.89 | RARA (0.82) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL29466100 | 0.89 | CYP3A4 (0.80) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL17885756 | 0.88 | RARB (0.81) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotene SCHEMBL995330 | 0.87 | RARB (0.88) | CYP3A4CYP26A1RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007646-A1 | METHODS FOR TREATING ACNE AND SKIN OILINESS WITH TAZAROTENE | BAUSCH HEALTH IRELAND LTD (IE) | 2026-01-08 | — | — | US | claimed |
| US-20250017854-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES | 1530065 B.C. LTD. (CA) | 2025-01-16 | — | — | US | claimed |
| US-12128137-B2 | Topical compositions and methods for treating skin diseases | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-10-29 | — | — | US | claimed |
| US-20230355640-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS | PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.) (PL) | 2023-11-09 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230233617-A1 | METHODS FOR DIFFERENTIATING STEM CELLS INTO DOPAMINERGIC PROGENITOR CELLS | SMARTDOPA AB (SE) | 2023-07-27 | — | — | US | claimed |
| CN-115968401-A | Method for differentiating stem cells into dopaminergic progenitor cells | JZ细胞技术公司 | 2023-04-14 | — | — | CN | claimed |
| EP-4146796-A1 | METHODS FOR DIFFERENTIATING STEM CELLS INTO DOPAMINERGIC PROGENITOR CELLS | JZ Cell Technologies AB (SE) | 2023-03-15 | — | — | EP | claimed |
| US-20220233439-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES | JPMORGAN CHASE BANK, N.A. | 2022-07-28 | — | — | US | claimed |
| CN-122036708-A | Nitric oxide donor type tazarotene derivative and preparation method and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12616673-B2 | Compounds for use in the treatment of leukemia | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-05 | — | — | US | disclosed |
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | KYOTO UNIVERSITY (JP) | 2026-02-26 | — | — | US | disclosed |
| US-20260007646-A1 | METHODS FOR TREATING ACNE AND SKIN OILINESS WITH TAZAROTENE | BAUSCH HEALTH IRELAND LTD (IE) | 2026-01-08 | — | — | US | disclosed |
| US-20260007646-A1 | METHODS FOR TREATING ACNE AND SKIN OILINESS WITH TAZAROTENE | BAUSCH HEALTH IRELAND LTD (IE) | 2026-01-08 | — | — | US | disclosed |
| US-11311482-B2 | Topical compositions and methods for treating skin diseases | BAUSCH HEALTH US, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| CN-114195672-A | Amide prodrugs of small molecule nuclear receptor modulators | 俄勒冈健康科学大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-107206086-B | Prevention and treatment of inflammatory conditions | GRI生物有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3967305-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | Syros Pharmaceuticals, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3044216-B1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | KCL THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007646-A1 | METHODS FOR TREATING ACNE AND SKIN OILINESS WITH TAZAROTENE | CUTA, PAOX, PPARG | CYP3A4 2524/4885CYP26A1 2205/4885RARB 36/4885 |
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | PKD1, RARB, PKD2 | CYP3A4 4441/4885CYP26A1 622/4885RARB 2/4885 |
| US-12616673-B2 | Compounds for use in the treatment of leukemia | PSMB3, PSMG3, PSMA3 | CYP3A4 2954/4885CYP26A1 1342/4885RARB 16/4885 |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | NR2F2, NR2E3, NR2C2 | CYP3A4 4728/4885CYP26A1 3962/4885RARB 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.